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Background. Myocardial inflammation following acute ischemic injury has been linked to poor cardiac remodeling and heart
failure. Many studies have linked myeloperoxidase (MPO), a neutrophil and inflammatory marker, to cardiac inflammation in
the setting of acute coronary syndrome (ACS). However, the prognostic role of MPO for adverse clinical outcomes in ACS
patients has not been well established. Methods. MEDLINE and Cochrane databases were searched for studies from 1975 to
March 2018 that investigated the prognostic value of serum MPO in ACS patients. Studies which have dichotomized patients
into a high MPO group and a low MPO group reported clinical outcomes accordingly and followed up patients for at least 30
days to be eligible for enrollment. Data were analyzed using random-effects model. Sensitivity analyses were conducted for
quality control. Results. Our meta-analysis included 13 studies with 9090 subjects and a median follow-up of 11.4 months. High
MPO level significantly predicted mortality (odds ratio (OR) 2.03; 95% confidence interval (CI): 1.40-2.94; P < 0 001), whereas it
was not significantly predictive of major adverse cardiac events and recurrent myocardial infarction (MI) (OR 1.28; CI: 0.92-
1.77, P = 0 14 and OR 1.23; CI: 0.96-1.58, P = 0 101, respectively). Hypertension, diabetes mellitus, and age did not affect the
prognostic value of MPO for clinical outcomes, whereas female gender and smoking status have a strong influence on the
prognostic value of MPO in terms of mortality and recurrent MI (metaregression coefficient -8.616: 95% CI -14.59 to -2.633,
P = 0 0048 and 4.88: 95% CI 0.756 to 9.0133, P = 0 0204, respectively). Conclusions. Our meta-analysis suggests that high
MPO levels are associated with the risk of mortality and that MPO can be incorporated in risk stratification models that
guide therapy of high-risk ACS patients.
1. Introduction
Cardiovascular disease is the leading cause of death world-
wide [1]. Acute coronary syndrome (ACS) has the worst
prognosis among cardiovascular diseases with significant
impact on morbidity and mortality. However, ACS patients
are a heterogonous population with variable pathologies
and clinical outcomes. Methods for risk stratification that
incorporate biological variables such as heightened inflam-
mation after cardiac injury are lacking. While troponin and
other cardiac markers have been shown to estimate the
degree of initial ischemic insult and long-term clinical events
[2], the prognostic value of markers of inflammation is not
well established.
Cardiomyocyte damage has been shown to initiate a sys-
temic and local inflammatory response that results in worsen-
ing cardiac remodeling and long-term cardiac and clinical
adverse events [3, 4]. This response initiates the mobilization,
recruitment, and activation of neutrophils and other inflam-
matory cells. Upon activation, neutrophils degranulate and
release inflammatory cytokines such as myeloperoxidase
(MPO) which aids in the clearance of dead cells and tissues
but has been shown to exert atherogenic and adverse vascular
effects [5, 6]. A robust body of well-designed, well-controlled
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foundational studies conducted in humans and animal
models collectively supports the premise that inflammation
and circulating inflammatory cells after myocardial infarc-
tion are detrimental for cardiac recovery [7, 8]. All these
properties make MPO a potential prognostic tool for predict-
ing future adverse clinical outcomes in ACS patients.
Studies that have been conducted to evaluate the prog-
nostic value of MPO in ACS patients showed discrepant
results [9, 10] and included a heterogeneous patient popula-
tion, and their sample size was insufficient to provide solid
conclusions. Therefore, we conducted this protocol-driven
systematic review and meta-analysis to explore the prognos-
tic value of MPO in ACS patients. We focused on studies that
included ACS patients and stratified patients’ outcomes
based on the plasma MPO levels.
2. Materials and Methods
We conducted this protocol-driven systematic review and
meta-analysis according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) [11].
We sought to compare the 30-day prognosis of ACS patients
with high vs. low MPO levels. MEDLINE, Scopus, and
Cochrane databases were searched from inception of myelo-
peroxidase until March 2018. Further details about the search
strategy and terms are shown in the Supplemental Table 1.
The references of relevant papers were also screened for
potential eligible studies. The abstracts of the American
Heart Association, American College of Cardiology, and
European Society of Cardiology were screened over the last
2 years for eligible studies.
To be eligible for inclusion in our analysis, studies had
to meet the following criteria: (1) patients are divided
according to a cutoff value of serum MPO into “high”
and “low,” (2) patients were followed up for at least 30
days, and (3) absolute numbers of clinical outcome events
were reported. Exclusion criteria were (1) irretrievable data,
(2) review articles and editorials, and (3) studies including
less than 50% subjects with an index diagnosis of ACS.
ACS was defined as either ST segment elevation myocar-
dial infraction (STEMI), non-STEMI, or unstable angina.
STEMI is defined according to previously published criteria
[12, 13] or the WHO criteria [14]. Non-STEMI is defined
as at least 10-15 minutes of chest pain at rest and elevated
biomarkers of myonecrosis, ST-segment deviation, or T-
wave abnormalities. Unstable angina was defined as a typ-
ical chest pain at rest with new ST segment changes and
peak cardiac troponin I levels within the normal range.
Prespecified outcomes of our analyses were mortality,
major adverse cardiac events (MACE), and recurrent
myocardial infarction. Because of the variability of the
definition of the composite of MACE, we included only
studies that specifically reported MACE or used a tradi-
tional definition of its components.
2.1. Data Extraction and Critical Appraisal. Two reviewers
(A.A-L and M.A) independently screened the full text of
the retrieved studies and used a standardized form to extract
the data from each study. For each outcome, absolute event
numbers were included and results are expressed as a ratio
of total participants with complete follow-up. Patients were
divided into 2 groups, above and below the median level of
MPO. Regarding reports that investigated the same subjects
at different follow-up time points, we extracted data pertain-
ing to outcomes from the longest follow-up report. We used
the Newcastle-Ottawa quality assessment scale (NOS) to
assess the quality of included studies [15].
2.2. Statistical Analyses. The prespecified outcomes of our
analyses were mortality, major adverse cardiac events
(MACE), and recurrent myocardial infarction. Summary
estimates were calculated as odds ratios (OR) with 95% con-
fidence intervals (CI) using the random-effects model based
on DerSimonian and Laird’s meta-analytic statistical method
[16]. Considering that the heterogeneity of the included stud-
ies might influence the prognostic effects, we prespecified the
use of the random-effects model to assess effect sizes. The I2
index was used to summarize the proportion of the total var-
iability in the estimate. The I2 statistic is derived from the Q
statistic and describes the percentage of total variation across
studies that is due to heterogeneity; values of 25%, 50%, and
75% correspond to low, moderate, and high heterogeneity,
respectively [17] [18]. Sensitivity analyses were performed
using the one-study-removed and the cumulative analysis
methods in order to assess the influence of each study on
the overall pooled results of the meta-analysis. We used
Egger’s test and visual inspection of Funnel plots to assess
for publication bias [19].
2.3. Metaregression Analysis. Using log-transformed OR as
dependent variable, metaregression analyses were performed
to determine whether the prognostic value of MPOwas mod-
ulated by prespecified study-level factors including age and
percentage of female gender, patients with index diagnosis
ACS, smoker, diabetes mellitus, and hypertension among
study populations. Metaregression was performed with unre-
stricted maximum-likelihood method (inverse variance-
weighted regression) on the event rate log-transformed
before being used as independent variables in linear metare-
gression analyses [20]. The statistical level of significance was
2-tailed P < 0 05. All statistical analyses were performed
using Comprehensive Meta-Analysis version 3.0 software
(Biostat Inc., New Jersey, USA).
3. Results
The final analysis included 13 studies that enrolled 9090
subjects with a median follow-up of 11.4 months. The
selection process is summarized in Figure 1. Interreviewer
agreement on study eligibility was 100%. The baseline char-
acteristics of the included patients are shown in Table 1.
Overall, patients with high MPO had similar baseline
characteristics compared to those with low MPO. The dif-
ferent definitions of MACE in the included studies in the
meta-analysis are shown in Supplemental Table 2. The
quality assessment of each included study is shown in
Supplemental Table 3.
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The primary endpoint, all-cause mortality, was signifi-
cantly higher in patients with high MPO compared to
those with low MPO (OR 2.03; CI: 1.40-2.94, P < 0 001)
(Figure 2). The incidence of MACE and recurrent myocar-
dial infraction trended higher among patients with high
MPO (OR 1.28; CI: 0.92-1.77, P = 0 14 and OR 1.23; CI:
0.96-1.58, P = 0 101, respectively) (Figures 3 and 4). The
heterogeneity in our analyses was moderate based on the
I2 statistic of 17%, 48%, and 77% for recurrent MI, mor-
tality, and MACE, respectively.
Metaregression analysis of the primary endpoints strati-
fied by baseline characteristics, such as age, prevalence of
hypertension, percentage of ACS in the study population,
and diabetes mellitus, showed no significant interactions
(Supplemental Figures 1-3). However, there was a
significant inverse correlation between female gender and
the prognostic value of MPO for both mortality (correlation
coefficient -4.23, 95% CI: -7.88 to -0.59, P = 0 02) and
recurrent MI (correlation coefficient -2.37, 95% CI: -4.69 to
-0.03, P = 0 047) (Supplemental Figures 1 and 3). On the
other hand, smoking showed a significant direct correlation
with the OR of recurrent MI; hence, the prognostic value of
high MPO on recurrent MI was greater among smokers
than nonsmokers (correlation coefficient 5.21, 95% CI: 1.08
to 9.34, P = 0 01) (Supplemental Figure 3).
3.1. Sensitivity Analyses. Sensitivity analyses using the “one-
study-removed” method did not show significant changes
in the summary odds ratio estimates for any outcome
assessed (Supplemental Figure 4). Cumulative meta-analysis
showed a relatively stable accumulation of evidence for
primary endpoints assessed (Supplemental Figure 5). We
also stratified the studies based on sample collection
method. The results were inconclusive for the sample
collection tube because there was a significant imbalance
with higher number of studies that utilized EDTA
collection tube compared to those using heparin or citrate
collection tubes, thus precluding a definitive conclusion
regarding the impact of sample collection method on the
prognostic value of MPO in our analysis.
We also stratified the studies based on sample collection
timing. There was heterogeneity in the sample collection
time in relation to the onset of chest pain as detailed in
Table 2. There was no correlation between the timing of
blood collection and the prognostic value of MPO in mortal-
ity (-0.00, 95% CI: -0.02 to 0.02, P = 0 99), MACE (-0.02,
95% CI: -0.15 to 0.11, P = 0 78), or recurrent MI (-0.00,
95% CI: -0.03 to 0.03, P = 0 99).
3.2. Publication Bias. No clear evidence of publication bias
was observed on visual inspection of the Funnel plots
Records identified through
MEDLINE database searching
(n = 3586)
Additional records identified
through Cochrane database
(n = 462)
Records after duplicates removed
(n = 4048)
Records excluded after title
and abstract screening
(n = 4021)
Full-text articles assessed
for eligibility
(n = 27)
Full-text articles excluded,
with reasons
(n = 14)
(i) >50% of their subjects
don’t have ACS (n = 8)
(ii) Unavailable absolute
number of events
according to MPO
grouping (n = 30)
(iii) Follow up less than 30
days (n = 2)
(iv) Outcomes of our interest
are not reported (n = 1)
Studies included in
qualitative synthesis
(n = 13)
Figure 1: Flow chart of search strategy.
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Table 1: Patients’ characteristics of the studies included in the meta-analysis.
STEMI
(%)
NSTEMI
(%)
UAP
(%)
MPO cutoff
value
Sample
size
Age
Female
(%)
Smoking
(%)
Diabetes
(%)
Hypertension
(%)
Apple et al.∗ [31]
≥50% of patients
have cTnI ≥ 0 09 NA
≤125.6mcg/L 172 57 ± 16 43 NR 24.9 57.9
>125.6mcg/L 285
Baldus et al. [34] 0 0 100
<350 μg/L 376 61 4 ± 10 5 28.7 42.5 8.2 35.4
≥350 μg/L 171 62 5 ± 10 4 31 40 12.5 36.9
Brugger-Andersen
et al. [30]
AMI 100 0
≤26.8mcg/L 142 64 ± 13 20.8 38.9 10.4 24.4
>26.8mcg/L 141
Cavusoglu et al. [38] 12 43 45
≤20.34 ng/mL 91 65 ± 9 3 0.0 32 59 84
>20.34 ng/mL 91 64 7 ± 10 8 0.0 43 34 83
Chang et al. [28] AMI 53.9 NA
<1150 ng/mL 95 59 9 ± 12 8 10.55 34.7 33.7 60
≥1150 ng/mL 33 64 3 ± 12 1 15.1 39.4 51.5 57.6
Eggers et al. [9] AMI 36.6 21.8
≤208.1 pmol/L 235
66 (55, 76) 33.9 17.2 16.2 37.3
>208.1 pmol/L 61
Kaya et al. [10] 100 0 0
≤68 ng/mL 37 56 ± 11 26 61 20 37
>68 ng/mL 36 57 ± 13 21 66 32 55
Koch et al.§ [26] 43 NA NA
≤306.3 pmol/L 396 63 7 ± 13 0 30.3 32.9 19.2 70.9
>306.3 pmol/L 267 65 ± 12 31.1 33 23.6 67.8
Morrow et al. [39] 0 35 65
≤884 pg/mL 762 61 (52, 69) 32.1 28.7 25.1 67.2
>884 pg/mL 762 61 (53, 70) 34 29.5 28.9 63.9
Mocatta et al. [27] 81.1 18.9 0
≤55 ng/mL 242 61 7 ± 11 0 19.9 NA 12.7 NR
>55 ng/mL 243
Oemrawsingh†
et al. [40]
0 0 100
<350 μg/L 376
62 (54, 69) 20 40 14 42
≥350 μg/L 171
Rahman et al. [32] 65 30 5
<285.5 pmol/L 30
NR 20 NR NR NR
≥285.5 pmol/L 70
Scirica et al. [29] 0 48.3 49.2
≤670 pg/mL 2507
64 35.1 25 32.3 74.6
>670 pg/mL 1845
STEMI: ST-elevation myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; UAP: unstable angina; MPO: myeloperoxidase; CTn1: cardiac
troponin I; AMI: acute myocardial infraction; NA: not available. Continuous variables are presented in either median or mean ± SD. Categorical variables are
presented in percentages. ∗Apple et al. reported that the median cardiac troponin of the whole cohort is 0.09 μg/L. †Oemrawsingh et al. is a longer follow-up
report of Baldus et al.’s study subjects. §Reported that ACS-negative patients are 10.8% of the study population.
Study name Statistic for each study
Odds
ratio
Lower
limit
Upper
limit
Z value P value
Events/total
High
MPO
Low
MPO
Apple 2007
Baldus 2003
Chang 2009
Eggers 2009
Kaya 2012
Koch 2014
Mocatta 2007
Rahman 2016
Scirica 2011
Overall
0.900
1.263
14.880
2.633
5.806
2.695
2.363
0.848
1.621
2.031
0.395
0.365
2.971
1.207
0.643
1.367
1.412
0.147
1.215
1.403
2.051
4.372
74.529
5.743
52.408
5.311
3.956
4.902
2.162
2.939
−2.051
0.368
3.285
2.432
1.567
2.864
3.272
−0.184
3.283
3.756
0.802
0.713
0.001
0.015
0.117
0.004
0.001
0.854
0.001
0.000
11.88
6.78
4.46
12.65
2.57
14.66
18.53
3.85
24.62
15 / 285
4 / 171
8 / 33
12 / 61
5 / 36
24 / 267
52 / 243
4 / 70
105 / 1845
10 / 172
7 / 376
2 / 95
20 / 235
1 / 37
14 / 396
25 / 242
2 / 30
90 / 2507
0.1 0.2 0.5 1 2 5 10
Relative
weightOdds ratio and 95% Cl
Figure 2: Forest plot for all-cause mortality. High myeloperoxidase level was associated with significantly higher risk of mortality (odds ratio
2.03; 95% confidence interval (CI): 1.403-2.939; P < 0 001).
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(Supplemental Figures 6-8). Our Egger’s regression test
did not show significant risk of publication bias
(P = 0 39 for all-cause mortality, 0.06 for MACE, and 0.2
for recurrent MI).
4. Discussion
Risk stratification for patients with ACS is an evolving field,
and the prognostic role of inflammatory markers such as
MPO has not been fully investigated. In this comprehensive
systematic review and meta-analysis, we confirm the strong
correlation between elevated plasma MPO levels and cardiac
outcomes, including mortality, among patients with acute
coronary syndrome. More importantly, our results were con-
sistent across multiple study designs and patient characteris-
tics. These results support a potential role for MPO as part of
multimarker risk stratification model to guide future individ-
ualized therapies to the highest risk population. Future pro-
spective studies examining the prognostic value of MPO in
comparison of other biomarkers of inflammation such as
high-sensitivity C-reactive protein (hs-CRP) are warranted.
Myocardial injury triggers a series of signaling events to
communicate with the bone marrow and peripheral blood
cells (PBCs) through processes that are just now being eluci-
dated. After myocardial infarction, circulating inflammatory
cells such as neutrophils are a poor prognostic indicator, in
part because of their contribution to infarct expansion and
impaired cardiac remodeling, thereby promoting the pro-
gression to adverse remodeling and heart failure [21, 22].
Indeed, this initial injury response may actually confer
long-term harm because reduction in the initial recruitment
of inflammatory cells can reduce infarct size and prevent
cardiac remodeling following cardiac injury [23]. In addition
to effects on the myocardium, circulating inflammatory cells
following ACS accelerate experimental atherosclerosis in
animal models thus initiating a vicious cycle; thus, this type
of cycle may contribute to recurrent coronary events in
humans [24]. Therefore, identifying markers of inflamma-
tion and inflammatory cell activity can help risk stratify
ACS patients and guide future therapies. MPO is a product
of inflammatory neutrophils during their degranulation
and can aid in the process of clearing dead cells. However,
MPO has been linked to atherosclerosis and recurrent coro-
nary events. MPO enhances LDL cholesterol oxidation,
hence destabilizes coronary atherosclerotic plaque [25].
Additionally, MPO limits endothelial-derived nitric oxide
bioavailability which impairs coronary vessel dilatation and
worsens cardiac ischemia [6].
Myeloperoxidase as a prognostic marker in ACS patients
has generated conflicting results in clinical studies. The
majority of clinical data has confirmed the prognostic value
of MPO in predicting mortality [9, 26–29], and our analysis
confirmed this correlation to be highly significant. However,
although there was strong correlation between MPO levels
Study name Statistic for each study
Odds
ratio
Lower
limit
Upper
limit
Z value P value
Events/total
High
MPO
Low
MPO
Apple 2007
Brügger-Andersen 2008
Chang 2009
Eggers 2009
Kaya 2012
Oemrawsingh 2011
Overall
1.895
0.674
1.003
1.497
4.125
1.500
1.278
0.869
0.361
1.001
0.752
1.184
1.086
0.921
4.132
1.257
1.005
2.981
14.366
2.073
1.773
1.608
−1.240
2.944
1.148
2.226
2.458
1.469
0.108
0.215
0.003
0.251
0.026
0.014
0.142
11.28
14.65
31.32
13.12
5.64
23.99
27 / 285
16 / 75
14 / 61
12 / 36
9 / 172
64 / 223
39 / 235
4 / 37
0.1 0.2 0.5 1 2 5 10
Relative
weightOdds ratio and 95% Cl
Figure 3: Forest plot for major adverse cardiac events (MACE). High myeloperoxidase showed a trend towards higher risk of MACE
(odds ratio 1.27; CI: 0.92-1.77, P = 0 14).
Study name Statistic for each study
Odds
ratio
Lower
limit
Upper
limit
Z value P value
Events/total
High
MPO
Low
MPO
Cavusoglu 2007
Eggers 2009
Kaya 2012
Koch 2014
Marrow 2008
Scirica 2011
Overall
2.319
0.806
5.435
2.500
1.280
1.050
1.231
1.050
0.318
0.252
0.592
0.965
0.841
0.960
5.120
2.045
117.236
10.550
1.696
1.311
1.578
2.081
−0.453
1.080
1.247
1.715
0.430
1.641
0.037
0.651
0.280
0.212
0.086
0.667
0.101
8.62
6.47
0.65
2.85
36.71
44.70
22 / 91
6 / 61
5 / 267
127 / 762
11 / 91
28/ 235
3 / 396
2 / 36 0 / 37
103 / 762
0.1 0.2 0.5 1 2 5 10
Relative
weightOdds ratio and 95% Cl
Figure 4: Forest plot for recurrent myocardial infraction (MI). High myeloperoxidase showed a trend towards higher risk of recurrent MI
(odds ratio 1.23; CI: 0.96-1.57, P = 0 101).
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and other clinical events such as MACE and recurrent myo-
cardial infarction, this association did not reach statistical
significance in individual trials or our analysis [9, 30, 31].
There are multiple factors that can explain the lack of this
correlation. Some of the studies were underpowered to reach
a valid conclusion especially in individual endpoints [10, 30,
32]. Other studies enrolled a heterogeneous population of
patients with chest pain (mixture of ACS and non-ACS).
Indeed, it has been shown that MPO levels correlate with
the severity of ACS pathology [33]. In accordance with these
findings, we found that the prognostic value of MPO was the
highest among studies with high proportion of AMI patients
[10, 27] compared to those with higher percentage of unsta-
ble angina subjects [29, 34]. Additionally, timing of sample
collection could have played a role in the variable results
since MPO level was significantly higher immediately after
STEMI [26, 35]. Although studies adopted different MPO
cutoff values, our analysis was primarily focused on the prog-
nostic value of MPO rather than its absolute value since the
included studies used different MPO assays. Therefore,
despite the fact that MPO cutoff value was not the same,
stratifying patients based on a certain MPO cutoff provided
valuable prognostic information in patients with acute coro-
nary syndrome.
We performed additional sensitivity analyses attempting
to unify the included studies based on methodology and sam-
ple collection. When we focused our analyses on studies that
reported using similar methodology, we observed consistent
prognostic value of MPO for all endpoints examined. Simi-
larly, we did not see significant interaction between most of
the baseline characteristics or time of sample collection and
the prognostic value of plasma MPO. Additionally, the pre-
dictive value of MPO for all-cause mortality and MACE
was consistent in the “one-study-removed” and cumulative
analyses suggesting the generalizability of our findings.
There are limitations to our analysis inherent in conduct-
ing a meta-analysis using published patient data and the
methodological differences among the included studies.
Included studies enrolled heterogeneous patient populations
and adopted different definition of clinical outcomes which
could have influenced the results of the pooled analyses.
While we attempted to address this limitation by using com-
prehensive sensitivity and metaregression analyses, we could
have failed to include other clinical parameters that were
not reported in the published manuscripts. Furthermore,
the sample withdrawal timing was different across the
included studies which could have influenced the results;
however, there was no significant correlation between the
time of sample withdrawal and the prognostic value of
MPO for any of the outcomes. Finally, statin therapy, which
is known to downregulate MPO expression [36], was not
reported in most of the included studies, and therefore, we
could not conduct sensitivity analysis based on the propor-
tion of patients receiving statin.
This meta-analysis attempted to focus on a homogeneous
population of studies with high percentage of ACS patients,
thus addressing some of the variability in the literature.
Our results have significant implications in clinical practice.
Integrating MPO in risk stratification models could have an
additional value in identifying patients at higher risk of
developing heart failure, recurrent ischemia, and clinical
events specially mortality. The predictive value of MPO is
more specific in patients with STEMI and high-risk
NSTEMI where the damage is higher and more inflamma-
tory cells are more activated [28, 37].
5. Conclusions
MPO is a powerful prognostic marker for clinical outcomes
in patients with acute coronary syndrome. Our results advo-
cate for more comprehensive risk assessment tools that
incorporate MPO to more personalized medical and invasive
management for patients with ACS. Further studies examin-
ing management strategies based on peak MPO level are
needed to assess the clinical utility of this novel biomarker.
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